Literature DB >> 27750448

Respiratory syncytial virus vaccines: an update on those in the immediate pipeline.

Susanna Esposito1, Giada Di Pietro1.   

Abstract

Respiratory syncytial virus (RSV) is among the most common causes of lower respiratory tract infection among infants and the elderly worldwide. Despite its long history, no licensed vaccine is available. Recently, advances in the knowledge of RSV biology and pathology as well as the development of new techniques to generate vaccine candidates have increased the number of promising vaccines. The aim of this review is to analyze RSV characteristics, to consider the history of RSV vaccines and to discuss RSV vaccines currently in development. Among the candidates in clinical trials, nanoparticle and subunit vaccines seem to be the most promising for pregnant women and the elderly, whereas live-attenuated or vector-based vaccines appear to be optimal for the pediatric population.

Entities:  

Keywords:  RSV; prevention; vaccines

Mesh：

Substances：

Year:  2016        PMID： 27750448     DOI： 10.2217/fmb-2016-0106

Source DB:  PubMed          Journal:  Future Microbiol        ISSN： 1746-0913            Impact factor:   3.165


  11 in total

1.  A unique combination adjuvant modulates immune responses preventing vaccine-enhanced pulmonary histopathology after a single dose vaccination with fusion protein and challenge with respiratory syncytial virus.

Authors:  Youri Lee; Eun-Ju Ko; Ki-Hye Kim; Young-Tae Lee; Hye Suk Hwang; Young-Man Kwon; Barney S Graham; Sang Moo Kang
Journal:  Virology       Date:  2019-05-28       Impact factor: 3.616

Review 2.  Maternal immunisation to improve the health of HIV-exposed infants.

Authors:  Angela M Bengtson; Alan M Sanfilippo; Brenna L Hughes; David A Savitz
Journal:  Lancet Infect Dis       Date:  2018-12-07       Impact factor: 25.071

Review 3.  The immunogenicity and safety of respiratory syncytial virus vaccines in development: A systematic review.

Authors:  Jing Shan; Philip N Britton; Catherine L King; Robert Booy
Journal:  Influenza Other Respir Viruses       Date:  2021-03-25       Impact factor: 4.380

Review 4.  Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children.

Authors:  Eric A F Simões; Louis Bont; Paolo Manzoni; Brigitte Fauroux; Bosco Paes; Josep Figueras-Aloy; Paul A Checchia; Xavier Carbonell-Estrany
Journal:  Infect Dis Ther       Date:  2018-02-22

Review 5.  Host Components Contributing to Respiratory Syncytial Virus Pathogenesis.

Authors:  Jonatan J Carvajal; Andrea M Avellaneda; Camila Salazar-Ardiles; Jorge E Maya; Alexis M Kalergis; Margarita K Lay
Journal:  Front Immunol       Date:  2019-09-12       Impact factor: 7.561

Review 6.  Role of Type I Interferon (IFN) in the Respiratory Syncytial Virus (RSV) Immune Response and Disease Severity.

Authors:  Diego R Hijano; Luan D Vu; Lawrence M Kauvar; Ralph A Tripp; Fernando P Polack; Stephania A Cormier
Journal:  Front Immunol       Date:  2019-03-26       Impact factor: 7.561

7.  Determining Immune and miRNA Biomarkers Related to Respiratory Syncytial Virus (RSV) Vaccine Types.

Authors:  Lydia J Atherton; Patricia A Jorquera; Abhijeet A Bakre; Ralph A Tripp
Journal:  Front Immunol       Date:  2019-10-09       Impact factor: 7.561

Review 8.  Vaccination against Paediatric Respiratory Pathogens.

Authors:  Sonia Bianchini; Alberto Argentiero; Barbara Camilloni; Ettore Silvestri; Anna Alunno; Susanna Esposito
Journal:  Vaccines (Basel)       Date:  2019-11-01

9.  Intranasal vaccination with a recombinant protein CTA1-DD-RBF protects mice against hRSV infection.

Authors:  Hai Li; Hu Ren; Yan Zhang; Lei Cao; Wenbo Xu
Journal:  Sci Rep       Date:  2021-09-20       Impact factor: 4.379

Review 10.  Global Perspectives on Immunization During Pregnancy and Priorities for Future Research and Development: An International Consensus Statement.

Authors:  Bahaa Abu-Raya; Kirsten Maertens; Kathryn M Edwards; Saad B Omer; Janet A Englund; Katie L Flanagan; Matthew D Snape; Gayatri Amirthalingam; Elke Leuridan; Pierre Van Damme; Vana Papaevangelou; Odile Launay; Ron Dagan; Magda Campins; Anna Franca Cavaliere; Tiziana Frusca; Sofia Guidi; Miguel O'Ryan; Ulrich Heininger; Tina Tan; Ahmed R Alsuwaidi; Marco A Safadi; Luz M Vilca; Nasamon Wanlapakorn; Shabir A Madhi; Michelle L Giles; Roman Prymula; Shamez Ladhani; Federico Martinón-Torres; Litjen Tan; Lessandra Michelin; Giovanni Scambia; Nicola Principi; Susanna Esposito
Journal:  Front Immunol       Date:  2020-06-24       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.